Teladoc, Inc. (TDOC) Stock Rating Reaffirmed by SunTrust Banks, Inc.
Teladoc, Inc. (NYSE:TDOC)‘s stock had its “buy” rating reissued by research analysts at SunTrust Banks, Inc. in a report issued on Friday. They currently have a $40.00 target price on the health services provider’s stock. SunTrust Banks, Inc.’s price objective points to a potential upside of 23.08% from the company’s current price.
Several other brokerages also recently weighed in on TDOC. Piper Jaffray Companies restated a “buy” rating and set a $32.00 price objective on shares of Teladoc in a research report on Friday, July 14th. Zacks Investment Research downgraded shares of Teladoc from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. BidaskClub downgraded shares of Teladoc from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Cowen and Company restated an “outperform” rating and set a $39.00 price objective (up previously from $36.00) on shares of Teladoc in a research report on Thursday, August 3rd. Finally, Cantor Fitzgerald restated a “hold” rating on shares of Teladoc in a research report on Monday, August 28th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $38.17.
Teladoc (NYSE:TDOC) opened at $32.50 on Friday. The company has a debt-to-equity ratio of 0.83, a current ratio of 5.08 and a quick ratio of 23.22.
Teladoc (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, November 1st. The health services provider reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.25). Teladoc had a negative return on equity of 21.59% and a negative net margin of 39.61%. The firm had revenue of $68.70 million for the quarter, compared to analyst estimates of $67.53 million. During the same quarter last year, the firm earned ($0.33) EPS. The company’s revenue was up 112.0% on a year-over-year basis. analysts forecast that Teladoc will post -1.57 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/11/04/teladoc-inc-tdoc-stock-rating-reaffirmed-by-suntrust-banks-inc.html.
In related news, insider Adam C. Vandervoort sold 53,806 shares of the stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $30.92, for a total value of $1,663,681.52. Following the sale, the insider now directly owns 33,008 shares of the company’s stock, valued at approximately $1,020,607.36. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Mark Hirschhorn sold 35,000 shares of the stock in a transaction dated Tuesday, October 17th. The shares were sold at an average price of $32.84, for a total transaction of $1,149,400.00. Following the completion of the sale, the vice president now directly owns 20,887 shares in the company, valued at $685,929.08. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 168,806 shares of company stock worth $5,430,382. Corporate insiders own 4.47% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. ETF Managers Group LLC acquired a new stake in shares of Teladoc during the 2nd quarter worth about $104,000. Bank of Montreal Can boosted its stake in shares of Teladoc by 214.2% during the 2nd quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock worth $123,000 after purchasing an additional 2,397 shares during the last quarter. Pacad Investment Ltd. acquired a new stake in shares of Teladoc during the 2nd quarter worth about $135,000. Fred Alger Management Inc. acquired a new stake in shares of Teladoc during the 2nd quarter worth about $139,000. Finally, Ameritas Investment Partners Inc. boosted its stake in shares of Teladoc by 134.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock worth $164,000 after purchasing an additional 2,707 shares during the last quarter.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.